We hypothesized that baseline blood levels of mucin-1 predict the risk of critical adverse outcome events (including AE-IPF, all-cause mortality, and lung transplantation) and accelerated pulmonary function decline in patients with IPF receiving pirfenidone treatment. This evidence concerns the gene MUC1 and idiopathic pulmonary fibrosis.